REPLY
Losartan for Microalbuminuria in Normotensive Type 2 Diabetes Mellitus
Adrienne A.M. Zandbergen, MD;
Marinus G.A. Baggen, MD, PhD; and
Rob J.Th. Ouwendijk, MD, PhD
20 April 2004 | Volume 140 Issue 8 | Pages 668-669
IN RESPONSE:
Regarding Dr. Mandal's first statement, when we calculated creatinine clearance with the Cockcroft-Gault formula (which corrects for inaccuracy of urine collection), it decreased 3.3% in the losartan group and increased 2.7% in the placebo group; this difference was not statistically significant. Furthermore, as is known from previous long-term, large-scale studies, creatinine clearance stabilizes after prolonged treatment with ACE inhibitors or angiotensin-receptor antagonists (1-3). These agents have been shown to reduce the decline in GFR and to preserve kidney function.
We agree that control of blood glucose is the most important factor in reducing the development and progression of diabetic nephropathy. However, since the difference in glycosylated hemoglobin levels between our 2 study groups was not statistically significant, our data do not suggest that the slightly lower glycosylated hemoglobin level in the placebo group is responsible for the observed stable creatinine clearance.
Also, many studies have shown that strict blood pressure control delays the onset and progression of kidney disease. Although the study by Schrier and colleagues is interesting, accumulating evidence from several well-conducted, large-scale studies suggests that ACE inhibitors and angiotensin-receptor antagonists have specific additive renal protective effects above the reduction in blood pressure in patients with type 1 or type 2 diabetes, with or without hypertension.
Since many factors contribute to diabetic kidney damage, prevention and treatment should also target multiple factors. In our opinion, agents inhibiting the renin-angiotensin system have been shown to be renoprotective and are very likely to have an additive effect in reducing kidney damage combined with strict blood glucose and blood pressure control. In addition, for renal disease, albuminuria is also a strong and independent risk factor for cardiovascular morbidity and mortality (4, 5). Reducing urinary albumin excretion might reduce cardiovascular disease and death.
The statements of Drs. Kario and Shimada are also very interesting. Blood pressure in our study patients was measured between 8:00 a.m. and 12:00 noon. Since we did not use ambulatory blood pressure monitoring, we cannot exclude the possibility that a reduction of nocturnal or specific morning blood pressure associated with losartan helped reduce urinary albumin excretion rate.
|
Author and Article Information
|
|---|
From Ikazia Hospital, 3083 AN Rotterdam, the Netherlands.
1. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ. 1999;319:24-5. [PMID: 10390455].[Free Full Text]
2. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60. [PMID: 11565517].[Abstract/Free Full Text]
3. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9. [PMID: 11565518].[Abstract/Free Full Text]
4. Rutter MK, Wahid ST, McComb JM, Marshall SM. Significance of silent ischemia and microalbuminuria in predicting coronary events in asymptomatic patients with type 2 diabetes. J Am Coll Cardiol. 2002;40:56-61. [PMID: 12103256].[Abstract/Free Full Text]
5. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 1992;340:319-23. [PMID: 1353802].[Medline]
About Letters
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
PubMed
Top
Author & Article Info
References
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
